"Designing Growth Strategies is in our DNA"

Positive Airway Pressure Devices Market Size, Share & Industry Analysis, By Product Type, By Device Configuration, By Application, By End User, and Regional Forecast, 2026-2034

Last Updated: November 20, 2026 | Format: PDF | Report ID: FBI119774

 

Positive Airway Pressure Devices Market Size and Future Outlook

Play Audio Listen to Audio Version

The global positive airway pressure devices market size was valued at USD 5.39 billion in 2025. The market is projected to grow from USD 5.79 billion in 2026 to USD 10.16 billion by 2034, exhibiting a CAGR of 7.3% during the forecast period.

The global Positive Airway Pressure (PAP) devices market comprises medical devices that deliver pressurized air through a noninvasive patient interface to maintain airway patency or provide respiratory support during sleep. The market includes fixed continuous positive airway pressure (CPAP), auto-adjusting positive airway pressure (APAP), and bilevel positive airway pressure (BPAP) devices, and advanced PAP systems used mainly for the treatment of obstructive, central, and mixed sleep apnea, hypoventilation, and selected chronic respiratory insufficiency conditions.

Demand is expanding, as more patients are identified through sleep studies and home sleep apnea testing. At the same time, awareness of the health consequences associated with untreated sleep-disordered breathing continues to improve. PAP therapy also aligns with the growing shift toward long-term home-based care, allowing patients to manage treatment without repeated hospital visits. At the same time, manufacturers are advancing pressure-adjustment algorithms, patient-comfort features, connectivity, humidification, and remote-monitoring capabilities. These developments are making therapy easier to initiate, supervise, and continue, supporting first-time device adoption and replacement demand among existing users.

ResMed Inc., Koninklijke Philips N.V., BMC Medical Co., Ltd., and Löwenstein Medical SE & Co. KG were among the leading participants in the market in 2025, supported by product development, distribution capabilities, and strategic initiatives, including new product launches, collaborations, and partnerships.

Connected PAP Platforms and Personalized Pressure Algorithms to Reshape Therapy Management

The market is gradually moving away from standalone PAP devices toward connected treatment platforms that combine pressure delivery with ongoing therapy-performance data. Current systems can capture parameters such as treatment hours, respiratory events, pressure requirements, mask leakage, and other indicators that help patients and providers understand therapy usage, adherence, and treatment-related parameters. This visibility allows common problems to be identified earlier and may reduce the need for some in-person follow-up visits.

Manufacturers are also improving auto-adjusting and bilevel algorithms that adjust pressure delivery in response to detected respiratory events and changing treatment requirements rather than relying solely on one fixed pressure. Digital applications increasingly provide therapy feedback, setup assistance, reminders, troubleshooting, and patient coaching. ResMed's current PAP platforms, for example, combine auto-adjusting or bilevel therapy with connected digital support. In contrast, Fisher & Paykel Healthcare's SleepStyle platform allows patients to review therapy information and mask-leakage data. The competitive focus is therefore shifting toward more personalized, connected, and data-driven therapy management.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Diagnosis of Sleep Apnea and Treatment Initiation to Increase PAP Device Demand

An increasing number of patients diagnosed with sleep apnea is a key factor supporting the positive airway pressure devices market growth. Obstructive sleep apnea can remain undetected for years as symptoms such as snoring, daytime sleepiness, poor concentration, and morning headaches are often overlooked or attributed to other health issues. Wider access to sleep specialists, greater awareness among healthcare professionals, and the growing use of home-based sleep testing are helping enable more previously undiagnosed patients to enter treatment pathways.

Following a confirmed diagnosis of obstructive sleep apnea, when treatment is indicated, PAP remains a well-established non-invasive therapy, particularly for patients experiencing excessive sleepiness or related symptoms. The American Academy of Sleep Medicine recommends PAP therapy for adults with OSA and supports initiation using either APAP devices at home or laboratory-based titration in appropriate patients. As diagnosis expands, first-time PAP device prescriptions and purchases can increase while simultaneously expanding the installed base of PAP devices that supports future replacement, upgrade, and premium-device demand.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Expected Impact on Market Growth Estimated Gross Market Growth Contribution (USD Billion)
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Rising prevalence and diagnosis of obstructive sleep apnea, supported by obesity, aging, and greater awareness of sleep-disordered breathing High 1.5 High High High
2 Expansion of sleep diagnostic testing, home sleep apnea testing, and growth in PAP therapy initiation High 1.2 High High Medium
3 Technological advancements in APAP, bilevel, and advanced PAP systems, including connected devices, remote monitoring, smart algorithms, and comfort features Medium-High 1 Medium High High
4 Increasing adoption of home-based PAP therapy, supported by improving reimbursement, insurance coverage, and DME/HME infrastructure Medium-High 0.85 Medium High High
5 Expanding installed PAP device base, replacement and upgrade cycles, portable-device demand, and improving access in emerging markets Medium 0.67 Medium Medium High
6 Others (physician awareness, expanding sleep-care infrastructure, product launches, geographic expansion, digital-health integration) Low 0.35 Low Low Medium
Total Gross Growth Contribution 5.57  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Drivers & Impact Forecasts

MARKET RESTRAINTS

Patient Discomfort and Inconsistent Long-Term Use to Restrain PAP Device Adoption

Although PAP therapy is clinically established, its real-world treatment effectiveness depends substantially on consistent patient adherence. Some users experience pressure intolerance, mask discomfort, air leakage, nasal dryness, claustrophobia, sleep disruption, or discomfort or inconvenience associated with wearing a PAP interface overnight. These issues can cause patients to reduce nightly usage, discontinue therapy, or consider alternative treatment options. From a market perspective, this creates an important restraint, as a PAP prescription does not necessarily result in sustained therapy adherence. Manufacturers have responded by introducing quieter airflow-generation systems, auto-adjusting pressure, expiratory pressure relief, integrated humidification, smaller systems, and digital coaching tools designed to improve the treatment experience.

However, adherence still depends on patient education, appropriate device setup, mask fitting, clinical follow-up, and troubleshooting. The AASM specifically recommends educational, behavioral, troubleshooting, and telemonitoring interventions during PAP initiation, reinforcing that successful therapy requires more than the device itself and requires ongoing patient engagement and support.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Expected Impact on Market Growth Estimated Reduction in Market Size (USD Billion)
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Patient discomfort, pressure intolerance, mask-related issues, and inconsistent long-term PAP adherence leading to therapy discontinuation High 0.5 High High Medium
2 Uneven reimbursement, affordability constraints, and limited access to sleep diagnosis and PAP therapy, particularly in developing markets Medium-High 0.35 High Medium Medium
3 Regulatory scrutiny, product recalls, quality-compliance requirements, and potential supply disruptions affecting PAP manufacturers Medium 0.23 Medium Medium Low
4 Others (alternative OSA therapies, limited specialist availability, patient preference, procurement constraints, and competitive pricing pressure) Low 0.12 Low Low Low
Total Market Reduction 1.2  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Expansion of Home-Based Sleep Care to Create New PAP Device Growth Opportunities

The shift toward home-based sleep apnea diagnosis and treatment represents an important growth opportunity for PAP device manufacturers. Traditionally, patients underwent laboratory-based sleep studies, specialist consultation, in-laboratory pressure titration, equipment setup, and follow-up before establishing routine therapy. The growing use of home sleep apnea testing, remote consultation, digital onboarding, connected PAP platforms, and remote therapy review is helping streamline the diagnostic and treatment pathway for suitable patients. This approach can reduce the time between suspected sleep apnea and treatment initiation, particularly where access to sleep laboratories and specialist appointments is constrained.

APAP devices are particularly suitable for home-based treatment initiation in appropriately selected patients, as adults can begin therapy without requiring initial in-laboratory pressure titration. AASM guidance specifically supports home initiation with APAP in suitable patients. As healthcare systems place greater emphasis on decentralized chronic care, manufacturers combining PAP hardware with remote monitoring, digital support, and streamlined clinical data sharing may be better positioned to reach previously underserved patient populations.

MARKET CHALLENGES

Reimbursement Rules and Uneven Access to Sleep Care to Challenge Market Expansion

The PAP device market operates across healthcare systems with varying reimbursement policies, diagnostic requirements, purchasing structures, and levels of patient affordability. In developed markets, insurance coverage can support broad device adoption, but reimbursement often depends on documented sleep testing, medical necessity, prescriptions, adherence requirements, and supplier documentation. These conditions can lengthen the treatment pathway or disrupt continued coverage when requirements are not met. In the U.S., Medicare separately defines coverage conditions for CPAP and bilevel respiratory-assist devices, illustrating how payer policies can directly affect product selection and utilization.

In many emerging economies, different barriers affect market access. Limited availability of sleep laboratories, specialist physicians, trained technicians, insurance coverage, and organized homecare networks can contribute to underdiagnosis and undertreatment among eligible patients. Manufacturers therefore may need to adapt commercialization strategies to local healthcare systems. They increasingly need localized pricing, distributor partnerships, clinician education, reimbursement support, and scalable diagnostic pathways to translate unmet clinical needs into sustained demand for PAP devices.

Segmentation Analysis

By Product Type

Auto-Adjusting Positive Airway Pressure Devices Lead Market Due to Flexible Pressure Delivery and Home Initiation

Based on product type, the market is segmented into fixed continuous positive airway pressure devices, auto-adjusting positive airway pressure devices, bilevel positive airway pressure devices, advanced positive airway pressure devices, and others.

Auto-adjusting positive airway pressure devices account for the largest market share as they can vary pressure through the night according to changing airway needs. This flexibility reduces dependence on a single fixed pressure and may improve comfort for users whose requirements shift with sleep stage, body position, congestion, or weight. APAP is also well suited to home-based treatment initiation, supporting faster setup for appropriate patients without laboratory titration.

The advanced positive airway pressure devices segment is projected to grow at a CAGR of 9.7% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Device Configuration

Routine Nightly Therapy and Broader Feature Integration Support Standard/Bedside PAP Devices Leadership

By device configuration, the market is classified into standard/bedside PAP devices and travel & portable PAP devices.

Standard/bedside PAP devices hold the largest market share, as most PAP therapy is intended for consistent overnight use at home rather than occasional travel. Bedside systems generally offer a broader combination of humidification, pressure-control features, connectivity, therapy-data storage, displays, and comfort settings than ultra-compact travel models.

The travel & portable PAP devices segment is estimated to grow at a CAGR of 13.0% during the forecast period.

By Application

Large OSA Treatment Population and Established PAP Use Boost Obstructive Sleep Apnea Segment Growth

By application, the market is classified into obstructive sleep apnea, central, complex & mixed sleep apnea, hypoventilation & chronic respiratory insufficiency, and others.

Obstructive sleep apnea dominates the market, as it is the principal clinical indication for routine CPAP and APAP therapy. In OSA, repeated upper-airway collapse during sleep interrupts breathing and sleep quality, while positive airway pressure helps keep the airway open. The treatment pathway is well established across sleep clinics and homecare settings, and AASM guidance supports PAP therapy for adults with clinically significant OSA. Moreover, the segment is projected to hold an 86.9% share in 2026.

The hypoventilation & chronic respiratory insufficiency segment is estimated to grow at a CAGR of 8.7% during the forecast period.

By End User

Long-Term Nightly Treatment and Remote Care Support Strengthen Homecare Settings Segment Growth

Based on the end user, the market is classified into homecare settings, sleep centers & specialty clinics, hospitals, and others.

Homecare settings account for the largest positive airway pressure devices market share, as sleep apnea is usually managed over the long term rather than through repeated inpatient treatment. After diagnosis and prescription, patients generally use PAP equipment during sleep at home, creating sustained demand for personal bedside systems and periodic replacement. Furthermore, the segment is set to hold an 82.6% share in 2026.

The sleep centers & specialty clinics segment is projected to grow at a CAGR of 5.6% during the forecast period.

Positive Airway Pressure Devices Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America Positive Airway Pressure Devices Market Size, 2025 (USD Billion)

To get more information on the regional analysis of this market, Download Free sample

North America held the largest market share in 2024, with a market value of USD 2.30 billion, and maintained its leading position in 2025, reaching USD 2.43 billion. The market is expected to grow steadily in the coming years, supported by the high diagnosed burden of obstructive sleep apnea, widespread use of CPAP and APAP therapy, and a large installed base of PAP users requiring periodic device replacement and upgrades. The U.S. benefits from a mature sleep-care ecosystem comprising sleep laboratories, pulmonologists, respiratory therapists, DME/HME providers, and well-established reimbursement pathways for qualifying PAP therapy.

U.S. Positive Airway Pressure Devices Market

In 2026, the U.S. market is expected to represent USD 2.40 billion, capturing 41.5% of global revenues.

Europe

Europe is expected to grow at a CAGR of 6.0% in the coming years, the third-highest globally, reaching USD 1.33 billion in 2026. The market is projected to expand on the back of established sleep-medicine infrastructure, growing recognition of untreated sleep apnea, and increasing adoption of home-based respiratory therapy. Major European countries have developed hospital, specialist sleep-clinic, and homecare networks that facilitate PAP diagnosis, prescription, and long-term monitoring.

U.K. Positive Airway Pressure Devices Market

The U.K. market is projected to reach USD 0.21 billion in 2026, accounting for 3.6% of global revenues.

Germany Positive Airway Pressure Devices Market

The market in Germany is expected to reach about USD 0.29 billion in 2026, representing roughly 5.0% of global revenues.

Asia Pacific

In 2026, the Asia Pacific market is predicted to be valued at USD 1.43 billion, ranking as the second-largest globally. The Asia Pacific market is expected to experience strong growth, as a large underdiagnosed sleep apnea population gradually enters formal diagnosis and treatment pathways. Increasing healthcare expenditure, expansion of private hospitals and sleep clinics, improving awareness of obstructive sleep apnea, and wider access to home sleep testing are supporting PAP adoption across China, India, Japan, Australia, Southeast Asia, and other markets.

Japan Positive Airway Pressure Devices Market

The market in Japan is projected to generate approximately USD 0.26 billion in 2026, contributing nearly 4.4% of global revenues.

China Positive Airway Pressure Devices Market

The market in China is expected to reach approximately USD 0.44 billion in 2026, contributing to 7.7% of global revenues.

India Positive Airway Pressure Devices Market

The market in India is expected to contribute approximately USD 0.20 billion in 2026, corresponding to about 3.5% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.06 billion in 2026. The Latin America market is anticipated to grow as sleep apnea awareness improves and access to respiratory diagnosis and treatment expands, particularly in Brazil and Mexico. A sizeable population affected by obesity, hypertension, cardiovascular conditions, and other risk factors associated with obstructive sleep apnea creates a substantial underlying need for PAP therapy.

The Middle East & Africa market is expected to expand from a comparatively smaller base, supported by healthcare infrastructure development, increasing recognition of sleep-disordered breathing, and improving availability of respiratory-care technologies. GCC countries are likely to remain important contributors owing to relatively high healthcare expenditure, advanced hospital infrastructure, growing obesity-related health burdens, and increasing investment in specialist and home-based care.

GCC Positive Airway Pressure Devices Market

In 2026, the GCC market is expected to generate approximately USD 0.08 billion, accounting for nearly 1.5% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Brand Leadership and Connected PAP Innovation to Shape Competitive Positioning

The global positive airway pressure devices market is moderately concentrated, with ResMed, Koninklijke Philips N.V., and BMC Medical Co., Ltd. forming the leading competitive group, followed by Löwenstein Medical, React Health, Yuwell, Fisher & Paykel Healthcare, and other regional manufacturers. Competition is increasingly centered on auto-adjusting PAP, bilevel and advanced therapy platforms, connected-device ecosystems, remote monitoring, compact travel systems, and patient-comfort features. ResMed maintains a particularly strong position through its broad PAP portfolio, large installed base, and digital sleep-care ecosystem, while Chinese manufacturers are strengthening their presence through competitive pricing and expanding international distribution.

Market participants also compete on reimbursement access, DME/HME relationships, clinical acceptance, regulatory approvals, and after-sales support. Over the forecast period, differentiation through digital integration, therapy personalization, portability, and geographic expansion is expected to become increasingly important as manufacturers seek to gain share in both mature and underpenetrated markets.

LIST OF KEY POSITIVE AIRWAY PRESSURE DEVICE COMPANIES PROFILED

  • ResMed Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • BMC Medical Co., Ltd. (China)
  • Löwenstein Medical SE & Co. KG (Germany)
  • React Health (U.S.)
  • Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (China)
  • Fisher & Paykel Healthcare Corporation Limited (New Zealand)
  • Resvent Medical Technology Co., Ltd. (China)
  • SEFAM (France)
  • Wellell Inc. (Taiwan)

KEY INDUSTRY DEVELOPMENTS

  • May 2026: ResMed and ŌURA formed a partnership intended to connect wearable-based sleep insights with sleep-health education and pathways to professional care, potentially helping more users enter formal sleep-apnea diagnosis and PAP-treatment pathways.
  • September 2025: BMC Medical announced the P5 series sleep respiratory/PAP device launch, adding another generation of sleep-therapy equipment to its expanding portfolio.
  • March 2025: Health Canada issued a Class II medical-device licence for Yuwell BreathCare PAP Positive Airway Pressure Units, including the YH-680A and YH-680B models.
  • January 2025: The FDA granted 510(k) clearance to BMC Medical's PAP Link PC Respiration Data Management Software, providing regulatory support for the company's connected PAP data-management ecosystem.
  • September 2024: BMC Medical formally opened its France office in Marcq-en-Barœul, strengthening its European commercial and service infrastructure for PAP and related sleep-respiratory products.

REPORT COVERAGE

The global positive airway pressure devices market report provides an in-depth analysis of all market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.


Report Scope and Segmentation

ATTRIBUTE  DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 7.3% from 2026 to 2034
Unit Value (USD Billion)
Segmentation By Product Type, By Device Configuration, By Application, By End User, and Region
By Product Type
  • Fixed Continuous Positive Airway Pressure Devices
  • Auto-Adjusting Positive Airway Pressure Devices
  • Bilevel Positive Airway Pressure Devices
  • Advanced Positive Airway Pressure Devices
  • Others
By Device Configuration
  • Standard/Bedside PAP Devices
  • Travel & Portable PAP Devices
By Application
  • Obstructive Sleep Apnea
  • Central, Complex & Mixed Sleep Apnea
  • Hypoventilation & Chronic Respiratory Insufficiency
  • Others
By End User
  • Homecare Settings
  • Sleep Centers & Specialty Clinics
  • Hospitals
  • Others
By Region
  • North America (By Product Type, By Device Configuration, By Application, By End User, and By Country)
    • U.S. (By Product Type)
    • Canada (By Product Type)
  • Europe (By Product Type, By Device Configuration, By Application, By End User, and By Country/Sub-region)
    • Germany (By Product Type)
    • U.K. (By Product Type)
    • France (By Product Type)
    • Spain (By Product Type)
    • Italy (By Product Type)
    • Scandinavia (By Product Type)
    • Rest of Europe (By Product Type)
  • Asia Pacific (By Product Type, By Device Configuration, By Application, By End User, and By Country/Sub-region)
    • China (By Product Type)
    • Japan (By Product Type)
    • India (By Product Type)
    • Australia (By Product Type)
    • Southeast Asia (By Product Type)
    • Rest of Asia Pacific (By Product Type)
  • Latin America (By Product Type, By Device Configuration, By Application, By End User, and By Country/Sub-region)
    • Brazil (By Product Type)
    • Mexico (By Product Type)
    • Rest of Latin America (By Product Type)
  • Middle East & Africa (By Product Type, By Device Configuration, By Application, By End User, and By Country/Sub-region)
    • GCC (By Product Type)
    • South Africa (By Product Type)
    • Rest of Middle East & Africa (By Product Type)

Research Methodology

1. Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major PAP Device Players

  • Collection of PAP-device-attributable revenues from annual reports, SEC filings, investor presentations, earnings releases, and company disclosures of major manufacturers such as ResMed, Philips Respironics, BMC Medical, Löwenstein Medical, React Health, Yuwell, Fisher & Paykel Healthcare, and others.
  • Estimation of company market shares based on PAP revenues, unit shipments, geographic presence, product portfolio, installed base, distribution reach, and replacement demand.
  • Exclusion of masks, accessories, ventilators, diagnostics, services, and unrelated respiratory-device revenues.

Approach 2: PAP Device Volume × ASP Analysis

  • Estimation of annual sales volumes for Fixed CPAP, APAP, Bilevel PAP, and Advanced PAP devices across key countries and regions.
  • Application of manufacturer-level ASPs by device type, geography, brand positioning, and procurement channel.
  • Separation of new therapy initiation from replacement/upgrade demand, wherever feasible.
  • Summation of country- and regional-level device revenues to derive the global market estimate.

Approach 3: Epidemiology, Diagnosis & PAP Adoption Model

  • Assessment of diagnosed and treatment-eligible populations for obstructive sleep apnea, central/complex/mixed sleep apnea, hypoventilation, and qualifying chronic respiratory insufficiency.
  • Mapping of diagnosed patients to PAP eligibility, therapy initiation, treatment penetration, and adherence levels.
  • Addition of replacement demand based on the installed PAP patient base and expected device replacement cycles.
  • Validation of epidemiology-derived demand against OEM shipment and revenue estimates.

2. Top-Down Approach

Approach 1: Country-Level Sleep & Respiratory Care Demand Analysis

  • Assessment of sleep-disordered breathing prevalence, diagnosis rates, healthcare expenditure, reimbursement coverage, insurance penetration, and sleep-care infrastructure across key countries.
  • Evaluation of home sleep testing, sleep-center capacity, PAP prescription patterns, DME/HME networks, and technology adoption.
  • Allocation of regional PAP demand using country-level treatment penetration, purchasing power, installed base, and replacement intensity.
  • Reconciliation of country and regional estimates with bottom-up OEM revenue and unit-volume calculations.

3. List of Key Sources

  • U.S. FDA
  • CMS
  • European Commission / EU MDR
  • PMDA / MHLW
  • NMPA
  • CDSCO
  • TGA
  • WHO
  • OECD
  • Eurostat
  • World Bank
  • American Academy of Sleep Medicine (AASM)
  • American Thoracic Society (ATS)
  • European Respiratory Society (ERS)
  • Peer-reviewed clinical and epidemiological studies
  • Company annual reports and SEC filings
  • Investor presentations and earnings releases
  • Product catalogs and regulatory databases
  • Product launches, approvals, recalls, and reimbursement updates

4. Primary Interviews

Supply-Side Interviews: 60%

  • Key Respondents: PAP device manufacturers, distributors, DME/HME providers, respiratory-equipment suppliers, sales executives, product managers, regional managers, and industry specialists.
  • Discussions focus on PAP device revenues, unit volumes, ASPs, product mix, replacement cycles, regional penetration, competitive positioning, and distribution trends.

Demand-Side Interviews: 40%

  • Key Respondents: Sleep physicians, pulmonologists, respiratory therapists, sleep-center professionals, hospital procurement teams, homecare providers, and other healthcare professionals.
  • Discussions focus on PAP prescribing patterns, patient eligibility, treatment initiation, adherence, device preferences, reimbursement, replacement behavior, and regional adoption trends.


Frequently Asked Questions

Fortune Business Insights says that the global market value stood at USD 5.39 billion in 2025 and is projected to reach USD 10.16 billion by 2034.

In 2025, the market value in North America stood at USD 2.43 billion.

The market is expected to exhibit a CAGR of 7.3% during the forecast period of 2026-2034.

The auto-adjusting positive airway pressure devices segment led the market by product type.

Rising diagnosis of sleep apnea and treatment initiation is driving market growth.

ResMed Inc., Koninklijke Philips N.V., BMC Medical Co., Ltd., and Löwenstein Medical SE & Co. KG are some of the major players in the market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 220
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann